NCT05567354View on ClinicalTrials.gov

A Study to Evaluate the Intranasal Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-103)

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

June 10, 2022

Primary Completion Date

August 31, 2022

Study Completion Date

August 31, 2022

Conditions
Recreational Drug Use
Interventions
DRUG

PF614

PF614 100 mg capsules

DRUG

Oxycodone

Oxycodone HCl IR 40mg

OTHER

Placebo

placebo powder

Trial Locations (1)

43212

Ohio Clinical Trails, Columbus

Sponsors
All Listed Sponsors
lead

Ensysce Biosciences

INDUSTRY